UCB (OTCMKTS:UCBJY) Downgraded by Zacks Research to “Hold”

UCB (OTCMKTS:UCBJY – Get Free Report) was downgraded by equities research analysts at Zacks Research from a “strong-buy” rating to a “hold” rating in a report released on Wednesday, Zacks reports.

Several other research analysts have also recently issued reports on the stock. Barclays cut shares of UCB from a “strong-buy” rating to a “hold” rating in a report on Monday, June 15th. Jefferies Financial Group upgraded shares of UCB from a “moderate sell” rating to a “hold” rating in a report on Monday, August 3rd. One analyst has rated the stock with a Strong Buy rating and three have given a Hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy”.

Get UCB alerts:

Get Our Latest Stock Analysis on UCBJY

UCB Trading Up 1.4%

Shares of UCB stock opened at $119.73 on Wednesday. The firm’s 50-day moving average is $128.90 and its 200 day moving average is $140.10. UCB has a 1 year low of $114.53 and a 1 year high of $168.76. The company has a current ratio of 1.38, a quick ratio of 1.04 and a debt-to-equity ratio of 0.20.

About UCB

(Get Free Report)

UCB SA is a Belgium-based biopharmaceutical company focused on developing and commercializing medicines for people living with severe neurological and immunological diseases. The company operates internationally, serving patients and healthcare providers across North America, Europe and other global markets.

Its neurology portfolio includes treatments such as Keppra and Briviact for epilepsy, Vimpat for partial-onset seizures and Fintepla for certain severe seizure disorders. In immunology, UCB markets Cimzia for conditions including rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis and Crohn’s disease, as well as Bimzelx for several inflammatory skin and joint conditions.

UCB traces its origins to 1928, when it was established in Belgium as Union Chimique Belge.

Featured Articles

• Five stocks we like better than UCB
• Aeluma’s Selloff Could Be Setting Up Its Next Big Move
• Crypto Bill Stalls, Smart Money Calls: Time to Buy the Dip?
• The September Scramble: Find Sanctuary in These 3 Defensive Dividend Stocks
• The Fed’s Rate Hike Could Backfire If Oil Prices Collapse

Receive News & Ratings for UCB Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UCB and related companies with MarketBeat.com's FREE daily email newsletter.